MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma by Slotkin, Emily K, Patwardhan, Parag P, Vasudeva, Shyamprasad D, de Stanchina, Elisa, Tap, William D, Schwartz, Gary K

Get full text

Abstract 2926: PNA as novel targeted cancer therapy for BRAFV600E mutant melanoma by Rothman, Jeffrey H., Surriga, Oliver, Vasudeva, Shyamprasad D., Ambrosini, Grazia, Ouerfelli, Ouathek, Schwartz, Gary K.

Get full text

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial by Schwartz, Gary K, Prof, Tap, William D, MD, Qin, Li-Xuan, PhD, Livingston, Michael B, Prof, Undevia, Samir D, MD, Chmielowski, Bartosz, MD, Agulnik, Mark, MD, Schuetze, Scott M, MD, Reed, Damon R, MD, Okuno, Scott H, Prof, Ludwig, Joseph A, MD, Keedy, Vicki, MD, Rietschel, Petra, MD, Kraft, Andrew S, Prof, Adkins, Douglas, Prof, Van Tine, Brian A, MD, Brockstein, Bruce, MD, Yim, Vincent, BA, Bitas, Christiana, BA, Abdullah, Abdul, BA, Antonescu, Cristina R, Prof, Condy, Mercedes, RN, Dickson, Mark A, MD, Vasudeva, Shyamprasad Deraje, MA, Ho, Alan L, MD, Doyle, L Austin, Prof, Chen, Helen X, Prof, Maki, Robert G, Prof

Get full text

Abstract 3255: MLN0128, an investigational selective TORC1/2 kinase inhibitor, demonstrates potent antitumor activity in preclinical models of soft tissue sarcoma by Patwardhan, Parag, Deraje, Shyamprasad Vasudeva, Tap, William D., De Stanchina, Elisa, Schwartz, Gary K.

Get full text